In the September issue of the FDA Group’s “Insider Newsletter,” Dr. Carmody discusses FDA’s proposed Quality Metrics program, new expectations for device cybersecurity, and a warning letter citing faulty study data.
Menu
Contact Us. We can help you accelerate your time to market, reduce costs, and protect patients
Other Pages
- Pharmaceutical Quality Consultant
- Quality Systems Consultant
- Life Sciences Training Program Consultant
- Life Sciences Quality Consultant
- CMC Implementation Consultant
- Analytical Method Validation Consultant
- Stability Program Expert
- GMP Quality Consultant
- GMP Training Consultant
- Accelerating Drug Development
- Transitioning From Academia To Regulated Drug Development
Let’s Get Started On A Collaborative Approach to Quality
Copyright © 2024 Build Quality Cultures in Pharma and Biopharma with Carmody QS.